ENOV earnings analysis
What we found in ENOV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Enovis Corporation's Q1 2026 results showed revenue of $589 million, which exceeded the consensus estimate by 3%. Gross profit improved to $365.5 million, pushing the gross margin to 62%. However, the company reported a net loss of $8.5 million, significantly narrower than losses reported in the previous year, but still missing the expected EPS of $0.81. The company reaffirmed its full-year revenue guidance of $2.31 billion to $2.37 billion despite facing various operational challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeded Estimates
- Revenue for Q1 2026 was $589 million, surpassing the consensus estimate of $571.6 million by 3%.
- Strong Gross Profit Growth
- Gross profit improved to $365.5 million, an increase of 10.0% from $332.2 million in Q1 2025.
- Adjusted EBITDA Growth
- Adjusted EBITDA rose to $103.6 million, up from $87.1 million in Q1 2025, reflecting strong operational performance.
- Improvement in Margins
- Gross margin increased to 62.0%, up from 59.4% in Q1 2025.
- Reconstructive Segment Growth
- The Reconstructive segment saw net sales increase by $30.8 million, or 10.8%, during the period.
- Cash Flow Increase
- Operating cash flow improved to $24.0 million compared to a negative $1.6 million in the prior year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Net Losses
- Net loss for Q1 2026 was $8.5 million, although improved from a loss of $55.7 million in Q1 2025.
- Divestiture Impact
- Sales decreased by $12.7 million due to the October 2025 divestiture of the Dr. Comfort Footcare Solutions product line.
- Potential Macroeconomic Headwinds
- Management highlighted risks related to geopolitical tensions and inflation affecting operational stability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
- Gross margin
- 62.0%
- Operating margin
- 1.1%
- Segment
- Prevention & Recovery
- Segment
- Reconstructive
What they said about what is next.
Full-year 2026 guidance reaffirmed with expected organic revenue growth between 4-6%.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 26, 2026
- Enovis Corporation reported a revenue of $2.248 billion for the year ended December 31, 2025, reflecting a 6.7% increase from the previous year. The company faced operating losses of approximately $1.124 billion,…
- 10-Q · November 6, 2025
- Enovis Corporation reported Q3 2025 results showing stronger-than-expected revenue and EPS, significantly surpassing consensus estimates. Although gross margins improved, the company incurred substantial goodwill…
- 10-Q · August 7, 2025
- Enovis Corporation reported its Q2 2025 results showing a significant increase in revenue and EPS compared to both the prior quarter and the same quarter last year. Notably, revenue reached $565 million, a 7.6% increase…
- 10-Q · May 8, 2025
- Enovis Corporation's Q1 2025 results reflect a strong recovery with revenue increasing by 8.2% year-over-year to $558.8 million, driven primarily by growth in the Reconstructive segment. Gross and operating margins…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ENOV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever